To the Editor:
We read with great interest the article by Marcellin et al. [1] evaluating the predictive value of week 4 viral response to peginterferon-alpha 2a and ribavirin combination therapy in patients with hepatitis C virus (HCV) genotype 1. They concluded that patients with a P3 log 10 drop in HCV RNA at week 4 have a high probability of achieving sustained virologic response (SVR), which is consistent with our previous study [2] .
Previous studies reported that the genetic polymorphism near the interleukin 28B (IL28B) gene (rs12979860 or rs8099917) is a strong baseline factor associated with the outcome of therapy [3] . However, this variable was not included in the study by Marcellin et al., probably because the actual treatment period in the study predated this finding [4, 5] . Given these predictors, i.e. week 4 viral response and a baseline variable, how should they be combined to predict response?
We evaluated the predictive value of week 4 viral response to combination therapy on SVR in 272 patients infected with HCV genotype 1b [6] . Overall, a P3 log 10 drop in HCV RNA at week 4 was a strong predictor of SVR. SVR was achieved in 77.0% of patients with rapid virologic response (RVR) or a P3 log 10 drop, whereas only 16.7% of patients with a <3 log 10 drop achieved SVR (p <0.0001). When patients were stratified based on the IL28B genetic polymorphism rs8099917, which corresponds to rs12979860 in more than 99% of Japanese ethnicity [7] , a P3 log 10 drop at week 4 was strongly predictive of SVR in patients with the favorable TT rs8099917 genotype (CC rs12979860 genotype). The SVR rate was 79.5% in patients with RVR or a P3 log 10 drop and 15.6% in patients with a <3 log 10 drop (p <0.0001). In contrast, among patients with an unfavorable TG/GG rs8099917 genotype, no differences were found in the SVR rate between patients with RVR or a P3 log 10 drop (20.0%) and those with a <3 log 10 drop (18.3%, p = 0.9265); the predictive value of week 4 response is low in this subset. In addition, the predictive value of complete early virologic response (EVR) for SVR is lower in patients with the unfavorable TG/GG genotype. The SVR rate was 81.6% in patients with complete EVR and 21.2% in patients without (p <0.0001), when patients had the favorable TT rs8099917 genotype. In contrast, the rate of SVR was 25.0% in patients with complete EVR and 18.0% in patients without (p = 0.7279), when patients had the unfavorable TG/GG genotype. Therefore, it appears to be difficult to identify patients with the unfavorable genotype of the genetic polymorphism near the IL28B gene who have a likelihood to achieve SVR by week 4 viral response, although it can identify patients with a high likelihood of achieving SVR in patients with the favorable genotype.
In contrast to our results, a previous large study by Thompson et al. [8] reported that patients who attained RVR showed high SVR rate regardless of the genetic polymorphisms near the IL28B gene (rs12979860), although they focused on patients with RVR and did not include patients with non-RVR but with a P3 log 10 drop at week 4. This discrepancy between their study and ours may be partly explained by the difference in the ethnicity of the study population. The study by Thompson et al. was based on patients from the IDEAL study including Caucasians, African Americans, and Hispanics, whereas all patients were Japanese Asians in our study. Similarly, the ethnicity was different between the population studied by Marcellin et al. and ours. Accordingly, the distribution of rs12979860 or rs8099917 genotypes and the rate of concordance between rs12979860 (analyzed in a study by Thompson et al.) and rs8099917 (analyzed in our study) would be different. For example, the rate of favorable homozygote (CC rs12979860 genotype and TT rs8099917 genotype) was largely different: 33.0% in Thompson's study and 76.1% in our study. Moreover, our study involved only patients infected with HCV genotype 1b. These factors should be adjusted when comparing the association between the genetic polymorphisms near the IL28B gene and the predictive value of week 4 viral response between studies. Nonetheless, the genetic polymorphism near the IL28B gene appears to have a strong impact on the predictive value of early viral response to therapy; the prediction of SVR by week 4 viral response may have to be modified based on this strong baseline predictive factor. 
Encephalopathy or hepatic encephalopathy?
To the Editor: We read with interest the paper by Ginès and co-authors on the management of critically-ill cirrhotic patients [1] . However, we have some concerns on the section on management of hepatic encephalopathy. The authors seem to base their recommendations on a 'statistical' rather than a pathophysiological definition of the syndrome, grouping under the heading 'severe hepatic encephalopathy' a set of different neuropsychiatric symptoms arising in critically-ill cirrhotic patients, to include mental abnormalities relating to sepsis, electrolyte imbalance, and even the side-or desired-effects of drugs such as opioids and benzodiazepines. Within this frame, they state that ammonia levels should not be measured, as they provide no clinical information nor do they relate to clinical outcomes. While we agree with the authors that patients with cirrhosis, especially if critically-ill, may present with more than one metabolic encephalopathy, and these may all contribute and worsen the clinical picture, it seems to us that an effort should be made to differentiate hepatic encephalopathy from other forms of metabolic/toxic neuropsychiatric disturbance. For example, we need to be reasonably sure that the encephalopathy we refer to in order to define fulminant hepatic failure is hepatic encephalopathy, as we would not want to list for transplant a patient with hepatitis who is confused because of hypoglycaemia, or opioid/benzodiazepine overdose. In this respect, ammonia levels seem useful, as they reflect hepatic failure and portal-systemic shunting [2] , they correlate with recognised, quantified indices of hepatic encephalopathy, and they predict the development of hepatic encephalopathy over time [3] . Notably, sepsis, electrolyte imbalance, and psychoactive drugs cause neuropsychiatric abnormalities in critically-ill patients with no liver dysfunction [4] : we would not diagnose these patients with hepatic encephalopathy, we would not expect them to be hyperammonaemic and we would not treat them with ammonia-lowering drugs such as non-absorbable disaccharides/antibiotics. Critically-ill cirrhotic patients are no exception. Should they present with more than one potential cause for neuropsychiatric dysfunction, each cause should be identified and treated according to its pathophysiology. Finally, there seems to be some confusion in Table 2 , in relation to the West Haven criteria [5] .
These are clinical criteria and they are described, although not in their exact, original form [5] , in columns 2 and 3 of the table. However, the table also depicts stages, characterized by parallel alterations in consciousness, cognitive/behavioural features, neurological findings, and electroencephalographic changes. Such correspondence has never been established, which is the reason why Conn and co-workers proposed the use of an index, not unlike the Child-Pugh score, combining the independent scores of five dimensions (mental state based on the West Haven criteria, Trail Making Test A, asterixis, electroencephalographic slowing and arterial ammonia levels) [5] . In addition, the classification of electroencephalographic changes reported in column 5 of the table does not correspond to either the one proposed by Conn et al. [5] or to more modern ones [6] , most likely in relation to a typo or an alignment problem. An errata corrige on the involuntarily misleading information provided in Table 2 of the paper might be necessary.
